A Case of Hand-Foot Syndrome with Pustules and Paronychia Induced by Sunitinib.
- Author:
Jee Woong CHOI
1
;
Shin Woo KIM
;
Seung Man WOO
;
Chong Hyun WON
;
Soyun CHO
Author Information
1. Department of Dermatology, Seoul National University College of Medicine, Seoul Boramae Hospital, Seoul, Korea. sycho@snu.ac.kr
- Publication Type:Case Report
- Keywords:
Hand-foot syndrome;
Paronychia;
Sunitinib
- MeSH:
Carcinoma, Renal Cell;
Gastrointestinal Stromal Tumors;
Hand-Foot Syndrome;
Indoles;
Paronychia;
Phosphotransferases;
Pyrroles;
Tyrosine;
United States Food and Drug Administration
- From:Korean Journal of Dermatology
2008;46(10):1384-1386
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
In January 2006, Sunitinib was approved by the US Food and Drug Administration for the treatment of advanced renal cell carcinoma and gastrointestinal stromal tumor. Sunitinib inhibits the receptor tyrosine kinases that are involved with various receptors whose functions are related to tumor growth, angiogenesis and metastatic progression. The cutaneous adverse reactions of hand-foot syndrome associated with sunitinib are well known, but there have been no previous reports on these reactions in the Korean medical literature. We report here on a case of hand-foot syndrome due to this drug, and we discuss the possible mechanism of hand-foot syndrome caused by sunitinib.
